Core Viewpoint - The company has received approval from the National Medical Products Administration for a Phase III clinical study of IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma, indicating accelerated development of innovative therapies for this condition [1] Group 1: Product Development - IMM0306 is a dual-target bispecific molecule that targets CD47 and CD20, making it the first of its kind to enter clinical stages globally [1] - The mechanism of IMM0306 involves inhibiting the CD47-SIRPα interaction to block the "don't eat me" signal, enhancing the activation of macrophages and NK cells while preferentially binding to CD20 to effectively eliminate malignant B cells with minimal toxicity [1] - The company holds global intellectual property and commercialization rights for IMM0306 as of the announcement date [1]
宜明昂科-B(01541.HK)：药品审评中心批准IMM0306治疗复发/难治性滤泡性淋巴瘤的III期临床研究方案